Synnerva is a privately held, early-stage pharmaceutical company focused on the development and commercialization of proprietary central nervous system (CNS) drug compositions allowing significant reduction of the effective doses and elimination of side effects.
The company has developed a new technological platform for the concurrent increase of CNS drug efficacy while dramatically reducing their side effects. Synnerva's method is based on a combination of generic, FDA-approved APIs with stimulators of vagal afferents. Its proprietary compositions of CNS drugs (levodopa for Parkinson's disease, morphine, amitriptyline for pain, valproate for epilepsy, etc) in low or sub-therapeutic doses with sub-therapeutic doses of glutamate antagonists and/or adrenomimetics lead to unusual synergistic enhancement of the therapeutic effects of CNS drugs that is not accompanied by side effects.
The company's concept has been proven in animal models validated for appropriate clinical indications. The company's portfolio of drugs improved by its compositions in vivo include levodopa, morphine, amphetamine, mematine, sodium valproate, and amitriptyline.